WEBULL
News
LTRN
2.640
+3.13%
0.080
Weekly Report: what happened at LTRN last week (0202-0206)?
Weekly Report · 3h ago
Weekly Report: what happened at LTRN last week (0126-0130)?
Weekly Report · 02/02 09:16
Weekly Report: what happened at LTRN last week (0119-0123)?
Weekly Report · 01/26 09:16
Lantern Pharma Showcases AI Platform for Rare Cancers
TipRanks · 01/23 13:08
Lantern Pharma Receives FDA Orphan Drug Designation For LP-284
NASDAQ · 01/20 15:14
Lantern Pharma gets orphan drug designation for LP-284 from FDA
TipRanks · 01/20 13:16
FDA Grants Orphan Drug Designation to Lantern Pharma's LP-284 for Soft Tissue Sarcomas
Reuters · 01/20 13:04
LANTERN PHARMA'S LP-284 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SOFT TISSUE SARCOMAS
Reuters · 01/20 13:00
Weekly Report: what happened at LTRN last week (0112-0116)?
Weekly Report · 01/19 09:17
Lantern Pharma’s treatment of soft tissue sarcoma granted orphan designation
TipRanks · 01/16 02:40
Lake Street Remains a Buy on Lantern Pharma (LTRN)
TipRanks · 01/13 15:17
Lantern Pharma establishes India AI center to industrialize RADR platform
TipRanks · 01/12 14:32
Lantern Pharma Announces Establishment Of A.I. Center Of Excellence And Advanced Agentic Labs In Bengaluru, India
Benzinga · 01/12 14:09
LANTERN PHARMA INC - PHASE 2 FOCUSES ON MULTI-DISEASE EXPANSION AND REVENUE ACCELERATION
Reuters · 01/12 14:06
Lantern Pharma Unveils AI Center of Excellence at Investor and Analyst Day
Reuters · 01/12 14:05
Lantern Pharma Unveils AI Center of Excellence and Major Platform Rollout at Investor and Analyst Event
Reuters · 01/12 14:01
Weekly Report: what happened at LTRN last week (0105-0109)?
Weekly Report · 01/12 09:17
Weekly Report: what happened at LTRN last week (1229-0102)?
Weekly Report · 01/05 09:16
Weekly Report: what happened at LTRN last week (1222-1226)?
Weekly Report · 12/29/2025 09:15
More
Webull provides a variety of real-time LTRN stock news. You can receive the latest news about Lantern Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.